» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

Legacy Foundation HBO2

Trial

Clinical Trial Title

A Pilot Study Comparing Acute Post-Radiation Hyperbaric Oxygen (HBO2) versus Trental and Vitamin E for Breast Cancer Patients Who Have Recently Completed Radiation Therapy as Part of Their Treatment Course

Trial Status

Open to Enrollment

Start Date

July 22, 2019

Trial Type

Cancer - Adult Oncology

Specific Condition

Breast cancer

Eligibility Criteria

Inclusion Criteria

  • Patient is currently undergoing treatment for breast cancer and is on one of two pathways:
  •     Pathway 1 involves lumpectomy with radiation therapy, recurrence years later, mastectomy and tissue expander with further radiation therapy
  •     Pathway 2 involves mastectomy and tissue expander, 6 weeks of radiation therapy, and an implant in 6 months
  • Undergone mastectomy with expander or implant reconstruction > 2 weeks before starting radiation therapy
  • Completed chest wall irradiation in the past 3 days
  • Willing to stop herbal medications as directed by provider
  • Willing to stop daily use of supplemental vitamin E (Multivitamin with vitamin E component is acceptable, vitamin E cream is also acceptable)
  • Willing to have photographs of chest area taken for research purposes only

Exclusion Criteria

  • Have final implant placed < 2 weeks before start of radiation therapy
  • Plan to place final impacts < 4 months from the completion of radiation therapy, if tissue expanders are intact during radiation therapy
  • Radiation completed more than 3 days prior to study start
  • Unwilling or unable to stop oral supplemental Vitamin E

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number

Central IRB

Principal Investigator Name

Enoch Huang, MD

Contact Name

Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Contact E-Mail

oncologyresearch@lhs.org

Last Updated: Wednesday, January 27, 2021 12:56:55 PM